Key clinical point: Studies show that clinical benefits can come from nonabstinence drinking reduction.
Major finding: Those achieving a reduction of just a few drinks a day can significantly improve in adverse consequences, mental health, and other outcomes.
Study details: Randomized trial of more than 1,000 patients treated with acamprosate, naltrexone, and psychological intervention.
Disclosures: Dr. Anton reported consulting and/or funding from Alkermes, Allergan, Indivior, Insys Life Epigenetics, and Laboratori Farmaceutico CT. Dr. O’Malley reported consulting and/or funding from Alkermes, Amygdala, Indivior, Mistubishi Tanabe, Opiant, and other sources. Dr. Falk reported no disclosures.
REPORTING FROM AAAP 2018
Must Reads in Addiction Medicine
Acute Illness and Cannabis Use in Adults, Ann Intern Med; ePub 2019 Mar 26; Monte, et al
Dual Receipt of Rx Opioids & Overdose Death, Ann Intern Med; ePub 2019 Mar 12; Moyo, et al
Opioid-Related Mortality in US by Opioid Type, JAMA Netw Open; 2019 Feb 22; Kiang, et al
Disparities in the Prescription of Opioids, JAMA Intern Med; ePub 2019 Feb 11; Friedman, et al